Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in ... MarketWatch (press release) SAN DIEGO, May 17, 2012 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was ... |
